Idiopathic pulmonary fibrosis (IPF) is the most common form of pulmonary fibrosis and the most common form of idiopathic interstitial lung disease. Patients living with IPF may experience breathlessness and/or a dry, persistent cough, with symptoms worsening as additional scar tissue builds up.

Today, we are taking a look at what's recently changed regarding idiopathic pulmonary fibrosis in relation to clinical guidance, FDA approvals, and clinical trials.

Current Idiopathic Pulmonary Fibrosis Guidance
Recent FDA Approvals for Idiopathic Pulmonary Fibrosis

Below is the most recent medication approved by the FDA that we anticipated being incorporated into future clinical guidelines: 

  • Jascayd (nerandomilast)
    • Boehringer Ingelheim
    • Approved: October 2025
    • Jascayd (nerandomilast) was approved in October 2025 to treat idiopathic pulmonary fibrosis. Two months later, in December, the FDA approved it for the treatment of progressive pulmonary fibrosis in adults.
Ongoing Clinical Trials Related to Idiopathic Pulmonary Fibrosis

The following are ongoing, Phase 3 clinical trials based in the United States that we anticipate may impact future idiopathic pulmonary fibrosis clinical guidelines and guidance statements.

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  • Boehringer Ingelheim
  • Anticipated Study Completion: April 2027

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

  • Bristol-Myers Squibb
  • Anticipated Study Completion: October 2026

Sign up for alerts to keep up with the latest guidelines and insights.

Copyright © 2026 Guideline Central, all rights reserved.